Global Allergy Diagnostics Market Report 2022


Key players in the allergy diagnostics market are BioMérieux SA, Danaher Corporation, HOB Biotech Group Corp. Ltd., HYCOR Biomedical, Lincoln Diagnostics Inc., Omega Diagnostics Group Plc, Siemens Healthineers AG, Thermo Fischer Scientific Inc, PerkinElmer Inc.

New York, March 29, 2022 (GLOBE NEWSWIRE) — announces the release of the “Allergy Diagnostics Global Market Report 2022” –
(Euroimmun AG), R-Biopharm AG, Alcon Laboratories, Inc., Abbott Laboratories, HollisterStier Allergy, NEOGEN Corporation, AESKU.GROUP GmbH, ACON Laboratories, Erba Group and Astra Biotech GmbH.

The global allergy diagnostics market is expected to grow from $4.62 billion in 2021 to $5.07 billion in 2022 at a compound annual growth rate (CAGR) of 9.78%. The growth is mainly due to companies reorganizing their operations and recovering from the impact of COVID-19, which had previously led to restrictive containment measures involving social distancing, remote working and the closure of business activities that resulted in operational challenges. The market is expected to reach $7.50 billion in 2026 at a CAGR of 10.30%.

The allergy diagnostics market consists of the sale of allergy diagnostic solutions by entities (organizations, individual traders, and partnerships) that are used to identify the allergen (substance causing an allergic reaction) in a human body. An allergy is a reaction of the immune system to an allergen that is not normally harmful to the human body.

Allergens are foreign substances that cause allergic reactions. Certain foods like peanuts, milk, eggs and wheat, pollen and animal dander are some examples of allergens.

Allergy diagnosis is a procedure used by a trained allergist to assess whether the body is allergic to a certain substance. A blood test, skin test, or elimination diet may be used as part of the examination.

The diagnostic procedure for allergies depends on the type of allergens and the mode of transmission.

The main types of allergy diagnostic tests are in vivo allergy testing and in vitro allergy testing. In vivo allergy tests are performed on the human body to identify the cause of the allergic reaction.

In vitro allergy testing is done in laboratories using test tubes and petri dishes to identify the substance causing the allergy. Major allergy diagnostic products include consumables, instruments and luminometers.

By allergens, the allergy diagnostics market is segmented into inhalant allergens, food allergens, and drug allergens. Major end users of allergy diagnostics include diagnostic laboratories, hospital laboratories, and academic and research institutes.

North America was the largest region in the allergy diagnostics market in 2021. Regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America , South America, the Middle East and Africa.

Rising number of cases of allergic diseases will propel the growth of the allergy diagnostics market. The increase in allergic diseases has been attributed to the increase in environmental pollution from traffic and many industries.

An allergic reaction is described as an abnormal immune system response to an allergen. Allergic diseases include anaphylaxis, allergic rhinitis (often called “hay fever”), food allergies, skin allergies, and allergic asthma.

Avoiding allergens is the most essential treatment for allergic disorders. Therefore, correct allergy diagnosis is crucial for effective allergy treatment.

For example, according to the EuroPrevall community survey report, in 2019 the prevalence of probable food allergies in adults was 0.3%, 1.4%, 2.1%, 2.8%, 3.3% and 5.6% in Athens, Reykjavik, Utrecht, Lodz, Madrid and Zurich in 2019. The most common allergy symptoms were oral allergy symptoms (81.6%), followed by skin allergy symptoms ( 38.2%) and rhinoconjunctivitis (29.5%). Thus, the increase in the prevalence of allergic diseases will further support the growth of the allergy diagnostics market.

The increase in the number of collaborations and partnerships between companies operating in the allergy diagnostics industry to invent new testing methods or improve existing ones is a recent market trend. For example, in July 2019, PerkinElmer, Inc. and EverlyWell, Inc. announced a new partnership to accelerate innovation and accessibility of consumer-initiated health testing by integrating PerkinElmer’s CLIA and CAP certified laboratory facilities. to the EverlyWell network of laboratory suppliers. PerkinElmer provides the knowledge behind EverlyWell’s panels for Lyme disease and food sensitivity testing, which are the first products to emerge from this collaboration. Both tests use dried blood drop tests, which have been used by doctors and hospitals for decades to identify biomarkers of disease with just a few drops of blood. They were developed by medical geneticists board-certified by PerkinElmer Genomics and validated on the EUROIMMUN EUROBlotOne® and EUROIMMUN AnalyzerTM systems.

In October 2021, IMA Group, a physician-founded network of integrated clinical research sites specializing in Phase II-IV clinical trials in multiple therapeutics, announced the acquisition of Diagnostics Research Group for an undisclosed amount. The acquisition gave IMA access to a wider range of patient populations and allows it to expand into the Southwestern United States.

It also expands IMA’s clinical research division and its network of more than 90 physical medical practices. Diagnostics Research Group (DXRG) is a San Antonio, Texas-based clinical research site with expertise in vaccine and medical device development, internal medicine, allergy, and fatty liver and lung disease.

The countries covered in the Allergy Diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the United Kingdom and the United States.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.


CONTACT: Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001